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Introduction {#sec006}
============

In 2014 Tomori Kanda\[[@pone.0227649.ref001]\] published his work about signal intensity (SI) increase on unenhanced T1 weighted magnetic resonance imaging (MRI), causing hyperintensities in the dentate nucleus (DN)-to pons and globus pallidus to thalamus after consecutive injections of gadolinium-based contrast agents (GBCAs). His important work was the beginning of an ongoing debate about the deposition of GBCAs in patient's brains.\[[@pone.0227649.ref001]--[@pone.0227649.ref018]\] It is shown in numerous studies on humans and in a few animal studies that there is a positive correlation between SI increase on unenhanced T1 weighted MRI and the gadolinium concentration in the brain.\[[@pone.0227649.ref019]--[@pone.0227649.ref025]\] Currently, the scientific interest focuses on the question whether all GBCAs or only a specific GBCA subtype is causing such hyperintensities. As free ionic gadolinium is toxic, GBCAs are applied as chelates. According to their chemical structure, two subtypes of GBCAs can be classified. GBCAs of the linear subtype partially and GBCAs of the macrocyclic subtype completely enclose gadolinium. On the one hand, the majority of studies provided evidence that linear GCBAs are stronger correlated with SI increase in the DN.\[[@pone.0227649.ref001], [@pone.0227649.ref003]--[@pone.0227649.ref007], [@pone.0227649.ref013]--[@pone.0227649.ref015], [@pone.0227649.ref017], [@pone.0227649.ref018], [@pone.0227649.ref020], [@pone.0227649.ref022]--[@pone.0227649.ref024], [@pone.0227649.ref026]--[@pone.0227649.ref043]\] On the other hand, SI increase was described after macrocyclic GBCA administration in a few studies that were controversial discussed between specialists due to their limitations.\[[@pone.0227649.ref003], [@pone.0227649.ref005], [@pone.0227649.ref007], [@pone.0227649.ref008], [@pone.0227649.ref017]\] It seems that the molecular structure of the GBCA ligand, which defines the GBCA subtype, is a crucial factor for the SI increase on unenhanced T1 weighted MRI.\[[@pone.0227649.ref044]\]

In 2017, as a consequence of the scientific debate, regulatory authorities (EMA, European Medicine Agency; FDA Food and Drug Administration) decided about safety issues using GBCAs during clinical work-up, which resulted in divergent actions between EU and USA.\[[@pone.0227649.ref025]\] Based on a precautionary approach in the European Union nearly all linear GBCAs were removed from the market, while the FDA issued a class warning for all GBCAs.

Until now, the majority of published animal studies about this topic were performed on rodents\[[@pone.0227649.ref023], [@pone.0227649.ref024], [@pone.0227649.ref045]--[@pone.0227649.ref049]\] the minority on large experimental animals.\[[@pone.0227649.ref025]\] So far, in veterinary medicine, no studies described a potential SI increase after multiple linear GBCA administrations in client-owned dogs. This species is of special clinical interest, as dogs will potentially face multiple MR examinations in veterinary medicine during treatment of tumors or during neurological diseases. Moreover, dogs play an indispensable role as animal model for translational research approaches. Therefore, the question arises if in dogs, similar to humans, an SI increase in the DCN is detectable after consecutive MR examinations or whether the number of GBCA administration is below the limit of detection for a visible SI increase on unenhanced T1-weighted MR images. This study followed the guidelines for standardized assessment of SI increase for retrospective MRI studies published from the European Gadolinium Retention Evaluation Consortium (GREC).\[[@pone.0227649.ref044]\]

In the current study, we aimed to retrospectively assess clinical data of dogs after multiple MRI examinations with intravenous administration of gadodiamide. Additionally, the brain of one dog, which was euthanized unrelated to this study, underwent an LA-ICP-MS measurement of gadodiamide 35 months after last MRI examination.\[[@pone.0227649.ref050]--[@pone.0227649.ref052]\] We hypothesized that there is an increased hyperintensity on non-enhanced T1 weighted sequences in the deep cerebellar nucleus (DCN) of dogs after multiple gadodiamide administrations and a detectable gadodiamide retention in the cerebellum of dogs with LA-ICP-MS.

Material and methods {#sec007}
====================

Dataset of patients {#sec008}
-------------------

This restrospective study was performed on MR imaging data sets of 18 client-owned dogs presented between August 2012 and October 2017 at the Clinic for Diagnostic Imaging at the Vetsuisse Faculty of the University of Zurich. Inclusion criteria was that the dogs had multiple (defined as two or more) MR examinations of the brain with intravenous administration of the linear GBCA gadodiamide at a dose of 0.15mmol/kg. Three patients did not undergo unenhanced T1-weighted imaging or were unreadable for study purposes and were excluded from this study. However, 15 client-owned dogs met the inclusion criteria and had a history of neoplastic or neurological disease as reason for MRI examination. Demographic and clinical characteristics of the all animals in the dataset is summarized in [Table 1](#pone.0227649.t001){ref-type="table"}. All animals underwent general anesthesia during MRI examination based on a standard anesthesia protocol. After premedication with butorphanol and continious intravenous lactated Ringer's infusion, general anesthesia was induced with propofol and maintained with isoflurane combined in oxygen and air. One research beagle dog cadaver, which was euthanized unrelated to this study, was used for dissection and sampling of the whole brain. Accordingly, the additional organ sampling, which was an add-on to the main study purpose, applied 3R requirements and maximized the scientific output from the dog. LA-ICP-MS was used for determination of Gd-concentration in the cerebellum.

10.1371/journal.pone.0227649.t001

###### Demographic and clinical characteristics.

![](pone.0227649.t001){#pone.0227649.t001g}

  animal       BW \[kg\]   number of GBCA applications   cumulated dose \[mmol/animal\]   time between last GBCA and last MRI \[days\]   gender             breed                       type of disease
  ------------ ----------- ----------------------------- -------------------------------- ---------------------------------------------- ------------------ --------------------------- -----------------------------------
  1            11.2        2                             3.36                             254                                            female, neutered   Spitz                       meningioma
  2            33.0        2                             9.90                             169                                            male               Labrador Retriever          meningioma
  3            37.0        3                             16.65                            98                                             male               Boxer                       unspecified recurrent brain tumor
  4            15.5        2                             4.65                             77                                             male, neutered     franz. Bulldogge            pituitary tumor
  5            24.6        2                             7.38                             92                                             female, neutered   Magyar Vizsla               meningioma
  6            6.0         2                             1.80                             137                                            female, neutered   Jack Russel Terrier         meningioma
  7            13.2        2                             3.96                             582                                            male, neutered     franz. Bulldogge            cushing
  8            1.8         2                             0.54                             138                                            male               Yorkshire Terrier           meningoencephalitis
  9            22.8        2                             6.84                             83                                             female, neutered   Katalanischer Schäferhund   meningoencephalitis
  10           29.0        2                             8.70                             24                                             male               Boxer                       unspecified recurrent brain tumor
  11           29.5        2                             8.85                             114                                            male, neutered     Collie                      meningioma
  12           22.7        2                             6.81                             374                                            male, neutered     Labrador Retriever          meningioma
  13           35.5        2                             10.65                            135                                            male               Boxer                       unspecified recurrent brain tumor
  14           8.5         2                             2.55                             217                                            male, neutered     Jack Russel Terrier         pituitary tumor
  15           22.4        3                             10.08                            106                                            female, neutered   Labrador Retriever          pituitary tumor
  16           11.4        3                             5.13                             552                                            female             beagle                      healthy
  **median**   **22.6**    **2**                         **6.83**                         **136**                                                                                        
  **min**      **1.8**     **2**                         **0.54**                         **24**                                                                                         
  **max**      **37.0**    **3**                         **16.65**                        **582**                                                                                        

Demographic and clinical characteristics of all dogs displayed with date of birth (DOB), age at last MRI \[months\], bodyweight (BW) \[kg\], number of GBCA applications, cumulated dose \[mmol/animal\], time between last GBCA and last MRI \[days\], gender, breed, and type of disease.

Imaging and data analysis {#sec009}
-------------------------

The analysis included whole-brain MR imaging obtained between 2016 and 2019 at the Vetsuisse Faculty Zurich. Imaging was performed with a 3.0-T MRI (Philips Ingenia, Philips Netherlands). Transverse unenhanced T1-weighted image parameters were as follows: Repetition time: 11.15--13.17 ms, Echo time: 5.116--6.125 ms, slice thickness: 0.7 mm, number of averages: 1, acquisition matrix: 0/228/227/0 and echo train length: 227.

Image analysis was performed independently by two of the authors (HR, PK). A picture archiving and communication system (Synapse^®^ PACS, Fujifilm) was used for all reading sessions. Evaluation of the images, including analysis of ROIs and the mean SI values, was performed with open source medical image viewer (Horos based upon OsiriX^TM^, 64-bit medical image viewer for OS X, Version 3 (LGPL-3.0)). Pre- and postcontrast images were subjectively compared and analyzed regarding presence of signal alteration in the region of the deep cerebellar nuclei (DCN). Regions of interest (ROI) were drawn on the unenhanced T1-weighted images on the central pons, and the DCN on both hemispheres. ([Fig 1](#pone.0227649.g001){ref-type="fig"}) The anatomically correct description of the DN in dogs is *Nucleus lateralis cerebelli*, which is the most prominent DCN. Accordingly, we use the more generalized term DCN instead of DN or *Nucleus lateralis cerebelli* to better reflect the canine anatomical situation. The correct placement of the ROI was confirmed by using T2-weighted images at the same section position for identification of the DCN in unclear cases. The DCN-to-pons SI ratio was calculated by using the following formula: $$DCN‐to‐pons\ SI\ ratio = \left( {mean\ SI\ of\ DCN} \right)/\left( {mean\ SI\ of\ central\ pons} \right).$$

The first and last MR examination of the dogs was used to calculate the SI ratio difference by substracting the first examination SI ratio from the last examination SI ratio.

![T1 weighted unenhanced images a dogs brain in transversal orientation at the level of DCN; Colored circles indicate ROI at the Pons (proximal circles) and DCN (distal circles) in the left and right hemisphere **A:** first examination precontrast, **B:** second examination precontrast 105 days after first examination; related SI measurements of the ROIs showing measured area in mm^2^, Mean, Min, Max and SD of SI in the ROI.](pone.0227649.g001){#pone.0227649.g001}

Cadaver sample preparation {#sec010}
--------------------------

The research beagle dog was euthananized according to another unrelated study (animal license number ZH057/17) in accordance to Swiss animal welfare act. As an add-on to the main study, the dog\'s brain was harvested directly after euthanasia. The left brain hemisphere was coronally cut into 0.5--1.0 cm slices and cryopreserved (at ^−^80°C). Deep cerebellar nuclei of the left cerebellum were cut into a 50-μm-thick section and fixed on a piece of cork with Tissue-Tek O.C.T. Compound (Sakura Finetek GmbH, Staufen, Germany). For chemical analysis, the deep cerebellar nuclei were cut in thin sections of 10-μm thickness with a cryotome and mounted on microscopic glass slides. Before the ablation process, microscopic images were recorded with a BZ-9000 inverted fluorescence/bright field microscope (Keyence, Osaka, Japan). The right hemisphere of the brain was formalin fixed (4% buffered formalin), paraffin embedded, and stored until further analysis.

Localisation of deep cerebral nuclei by bench-top μXRF {#sec011}
------------------------------------------------------

For the localisation of deep cerebral nuclei, an M4 Tornado bench-top μXRFinstrument (Bruker Nano GmbH, Berlin, Germany) was used. The rhodium X-ray tube was supplied with a voltage of 50 kV and a current of 600 μA throughout the measurements. The emitted X-ray fluorescence was detected by a silicon drift detector (XFlash® 5030, Bruker Nano GmbH, Berlin, Germany). Spatial resolution was approximately 25 μm. Each pixel was measured twice for 200 ms at a pressure of 20 mbar. The data was evaluated using the software ESPRIT HyperMap (Bruker Nano GmbH, Berlin, Germany).

Standard preparation for LA-ICP-MS {#sec012}
----------------------------------

For calibration, 11 matrix-matched gelatine standards in a concentration range from 0 ng/g to 600 μg/g were created. For this purpose, a 1000 μg/g gadolinium (Gd) ICP-MS standard (Fluka Analytical, St. Gallen, Switzerland) was diluted and combined with gelatine of highest purity (Grüssing GmbH, Filsum, Germany) resulting in standards with a gelatine content of 10% (w/w). The suspension was homogenized by heating the standards to a temperature of 50°C and the usage of a vortex mixer. Afterwards, 10 μm thin slices of each standard were prepared via a CryoStar NX70 Cryostat (Thermo Fisher Scientific, Waltham, USA). The thin slices of the standards where then mounted onto a microscopic slide.

The Gd concentration in the gelatine standards was confirmed by ICP-TQMS (iCAP TQ, Thermo Fisher Scientific, Waltham, USA) analysis of the digested standards. For digestion, 500 μL concentrated nitric acid (Merck Chemicals GmbH, Darmstadt, Germany) and 100 μL 35% (w/w) hydrogen peroxide (Acros Organics, Geel, Belgium) were added to around 50 mg of each gelatine standard. The mixture was then heated to a temperature of 70°C until complete digestion. Afterwards, the digests were diluted and a rhodium (Rh) ICP-MS standard (SCP Science, Baie-D'Urfe, Canada) was added as an internal standard. The concentration was determined using an external Gd calibration in a range from 0 pg/g to 30 ng/g consisting of 12 standards. Again, Rh was used as an internal standard.

LA-ICP-MS measurements {#sec013}
----------------------

For elemental mapping of the Gd distribution, the hyphenation of an LSX 213 G2+ (Cetac Technologies, Omaha, USA) laser ablation system equipped with a HelEx II cell (Teledyne Cetac Technologies, Omaha USA) and an ICP-MS 2030 (Shimadzu, Kyoto, Japan) was used. For ablation, a spot size of 10 μm in combination with a stage speed of 30 μm/s was chosen. Laser energy was optimized for each individual sample to allow for quantitative ablation of the sample with minor ablation of the object slide. Ablated particles were washed out by a constant helium flow of 800 mL/min. For more efficient transportation, a daily tuned argon flow was added on the line to the micro torch of the ICP-MS system. A wet argon plasma with an RF power of 1200 W was used for the ionisation. The ionized analytes were led through a nickel interface and were analysed by an SQ-KED setup.

For quantification, the previously described matrix-matched Gd gelatine standards were used. On each standard, 11 lines with an ablation time of 20 s per line were ablated with the same parameters as used for the sample. The first line of each recording was discarded for consistency reasons.

All data evaluation was performed using the software ImaJar (developed by Robin Schmid, Muenster, Germany).

Statistics {#sec014}
----------

Statistical data was analyzed by using SPSS (IBM^®^ SPSS^®^ Statistics, version 25, 64-bit-version, IBM, Chicago, Ill). Due to the limited number of available cases, data was defined as non-normally distributed and quantitative data was presented with median (range). Non-parametrical tests were used to compare SI ratio differences between 2 independent observers (Mann-Whitney U test). Inter-rater reliability was assessed based on Intraclass-Correlation-Coefficient (ICC) in a range from 0.0 to 1.0, whereby large numbers mean better reliability. One-sample t-tests were used to examine if the mean SI ratio differences between first and last examination were different from 0. A p-value of \< 0.05 was considered significant.

Results {#sec015}
=======

Cinical and demographic aspects {#sec016}
-------------------------------

An overview about the demographic and cinical characteristic of the dataset is available provided as [Table 1](#pone.0227649.t001){ref-type="table"}. The mean age of all dog patients included was 96.20 (31--157) months. The animals gender was divided as followed: male (5), male castrated (5), female castrated (5). As this was a restrospective clinical study, the dogs were of different breeds: Boxer (3), Border Collie (1), French Bulldog (2), Jack Russel Terrier (2), Catalan Scheepdog (1), Labrador Retriever (3), Magyar Vizsna (1), Spitz (1), Yorkshire Terrier (1). Contrast media injection protocols were the same for all animals, as they followed a clinical standard operation procedure with 0.15 mmol/kg gadodiamide for each MRI examination. The time between the MRI examinations was caused by the clinical work-up and was in median 136 (24--582) days.

Additionally, one research beagle dog cadaver was included into this study, which was euthanized for another unrelated study. The research beagle dog was used for different studies including repetitive gadodiamide administrations in MRI before his termination. It was a 52 months old, female castrated beagle dog with 11.4 kg body weight. The contrast media injections of the dog were as followed: November 2013 (0.1 mmol/kg gadodiamide), December 2013 (0.1 mmol/kg gadodiamide), June 2015 (3 x 0.05 mmol/kg gadodiamide). Accordingly, the last gadodiamide injection was 35 months before termination. Following the 3R requirements, the brain of the dog was sampled and used for chemical analysis, as this was not possible to perform with the retrospectively examined clinical patient population.

MRI data {#sec017}
--------

Unenhanced T1-weighted imaging were independenly analyzed by two observers (HR, PK). A summary of all measurements are provided as [Table 2](#pone.0227649.t002){ref-type="table"}. SI values of the DCN and Pons as well as the SI ratios and the SI ratio differences between the first and the last examination of the left and right hemisphere are summarized in [Table 3](#pone.0227649.t003){ref-type="table"}. Based on non-parametric Mann-Whitney U tests, no significant differences were detectable between both observers at a significance level of p\< 0.05 (SI DCN left (p = 0.988), SI Pons left (p = 0.882), SI ratio left (p = 0.329), SI DCN right (p = 0.976), SI Pons right (p = 0.894), Si ratio right (p = 0.605), SI ratio difference left (p = 0.756), SI ratio difference right (p = 0.548).

10.1371/journal.pone.0227649.t002

###### SI ratio differences.
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               observer 1   oberver 2                                                                                                                                                            
  ------------ ------------ ----------- ----------- ---------- ---------- ----------- ------------ ------------ ---------- ---------- ----------- ---------- ---------- ----------- ------------ ------------
  1            125.053      126.691     0.987       124.613    125.208    0.995                                 124.606    126.761    0.983       125.667    125.343    1.003                     
  1            277.428      281.183     0.987       280.295    287.391    0.975       0.000        -0.020       272.885    282.305    0.967       279.496    285.953    0.977       -0.016       -0.025
  2            366.1        372.94      0.982       355.652    361.514    0.984                                 471.703    468.736    1.006       460.095    466.525    0.986                     
  2            362.487      359.643     1.008       360.836    355.127    1.016       0.026        0.032        362.179    360.978    1.003       357.583    361.620    0.989       -0.003       0.003
  3            172.257      173.655     0.992       174.972    176.618    0.991                                 173.935    176.551    0.985       176.775    177.906    0.994                     
  3            178.492      183.944     0.970       179.350    184.430    0.972       -0.022       -0.018       179.023    183.55     0.975       175.918    186.732    0.942       -0.010       -0.052
  3            422.66       449.613     0.940       437.129    459.989    0.950       -0.052       -0.040       419.148    455.787    0.920       429.200    458.764    0.936       -0.066       -0.058
  4            175.919      172.502     1.020       172.275    175.804    0.980                                 172.698    175.878    0.982       173.125    175.544    0.986                     
  4            343.066      340.951     1.006       344.929    346.556    0.995       -0.014       0.015        349.659    342.713    1.020       350.028    348.415    1.005       0.038        0.018
  5            614.737      628.453     0.978       639.614    647.677    0.988                                 622.014    632.662    0.983       634.766    652.891    0.972                     
  5            643.488      642.776     1.001       647.769    635.415    1.019       0.023        0.032        648.4      653.633    0.992       650.581    640.549    1.016       0.009        0.043
  6            423.872      427.325     0.992       430.475    429.126    1.003                                 430.852    439.226    0.981       431.025    431.684    0.998                     
  6            1337.617     1308.215    1.022       1350.109   1308.886   1.031       0.031        0.028        1345.156   1341.79    1.003       1347.488   1345.814   1.001       0.022        0.003
  7            997.558      993.47      1.004       995.635    1003.037   0.993                                 988.921    1000.341   0.989       998.839    1004.823   0.994                     
  7            590.895      589.339     1.003       580.894    577.059    1.007       -0.001       0.014        581.192    591.546    0.982       572.667    593.458    0.965       -0.006       -0.029
  8            121.255      124.544     0.974       122.963    116.500    1.055                                 122.184    124.16     0.984       122.953    117.417    1.047                     
  8            149.632      134.637     1.111       129.449    129.388    1.000       0.138        -0.055       148.141    138.991    1.066       126.260    128.084    0.986       0.082        -0.061
  9            97.817       88.727      1.102       95.320     90.399     1.054                                 98.402     90.347     1.089       95.379     90.695     1.052                     
  9            97.977       95.76       1.023       97.402     95.758     1.017       -0.079       -0.037       97.07      95.184     1.020       97.455     95.400     1.022       -0.069       -0.030
  10           131.948      133.301     0.990       130.471    136.535    0.956                                 128        134.089    0.955       130.690    137.105    0.953                     
  10           120.822      125.631     0.962       121.811    123.667    0.985       -0.028       0.029        112.01     122.136    0.917       110.887    122.901    0.902       -0.037       -0.051
  11           133.753      134.268     0.996       134.603    134.671    0.999                                 134.295    133.571    1.005       136.521    136.333    1.001                     
  11           129.713      124.613     1.041       129.773    121.503    1.068       0.045        0.069        130.938    126.121    1.038       127.061    122.018    1.041       0.033        0.040
  12           76.143       78.517      0.970       77.633     78.761     0.986                                 73.75      78.213     0.943       76.652     79.258     0.967                     
  12           86.485       95.423      0.906       85.735     99.646     0.860       -0.063       -0.125       84.317     95.434     0.884       85.253     96.134     0.887       -0.059       -0.080
  13           707.581      726.456     0.974       690.724    692.353    0.998                                 713.182    735.14     0.970       695.767    704.060    0.988                     
  13           626.935      637.184     0.984       611.346    622.576    0.982       0.010        -0.016       615.634    624.683    0.986       629.760    611.041    1.031       0.015        0.042
  14           504.183      517.667     0.974       514.801    519.431    0.991                                 509.696    522.529    0.975       517.467    513.294    1.008                     
  14           136.327      138.181     0.987       137.012    139.957    0.979       0.013        -0.012       136.547    138.476    0.986       136.415    138.630    0.984       0.011        -0.024
  15           101.85       96.083      1.060       101.685    94.867     1.072                                 103.259    96.485     1.070       103.662    96.792     1.071                     
  15           123.488      124.719     0.990       124.653    123.724    1.008       -0.070       -0.064       125.277    123.168    1.017       125.057    127.250    0.983       -0.053       -0.088
  15           662.897      672.978     0.985       662.978    672.459    0.986       -0.075       -0.086       659.586    677.183    0.974       660.568    680.373    0.971       -0.096       -0.100
  **median**   ** **        ** **       **0.990**   ** **      ** **      **0.994**   **-0.001**   **-0.016**   ** **      ** **      **0.985**   ** **      ** **      **0.989**   **-0.006**   **-0.029**
  **min**      ** **                    **0.906**                         **0.860**   **-0.079**   **-0.125**   ** **                 **0.884**                         **0.887**   **-0.096**   **-0.100**
  **max**      ** **        ** **       **1.111**   ** **      ** **      **1.072**   **0.138**    **0.069**    ** **      ** **      **1.089**   ** **      ** **      **1.071**   **0.082**    **0.043**

SI ratio differences from the two observers for each single dog, as well as median, min and max of each measurement

10.1371/journal.pone.0227649.t003

###### Measurement data.
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                                   observer 1   observer 2   Mann-Whitney U test                                                             
  --------------------------- ---- ------------ ------------ --------------------- ------- ------- -------- ------- -------- ------- ------- -------
  SI DCN left                 30   76           1338         358                   307             74       1345    361      308             0.988
  SI Pons left                30   79           1308         360                   306             78       1342    366      311             0.882
  SI ratio left               30   0.906        1.111        0.999                 0.041   0.862   0.884    1.089   0.989    0.043   0.158   0.329
  SI DCN right                30   78           1350         358                   308             77       1347    361      310             0.976
  SI Pons right               30   79           1309         359                   305             79       1346    365      311             0.894
  SI ratio right              30   0.860        1.072        0.997                 0.039   0.701   0.887    1.071   0.991    0.040   0.227   0.605
  SI ratio difference left    15   -0.079       0.138        -0.002                0.055   0.896   -0.096   0.082   -0.010   0.048   0.451   0.756
  SI ratio difference right   15   -0.125       0.069        -0.011                0.051   0.402   -0.100   0.043   -0.021   0.045   0.098   0.548

Measurements of observer 1 and 2 displayed as mean, min, max and SD for DCN and Pons, SI ratio and SI ratio difference in the left and right hemisphere. One-sample t-test for both hemispheres, testing for differences from 1 (for SI ratios), respective from 0 (SI ratio differences). Additional p- values of the Mann-Whitney-U test comparing results of oberserver 1 and 2.

The ICC showed very good agreement between both observers ([Table 3](#pone.0227649.t003){ref-type="table"}). For all analyses, ICC was between 0.863 (SI ratio difference right hemisphere)-- 0.999 (SI DCN left, SI Pons left, SI DCN right, SI Pons right).

SI ratio DCN-to-pons showed no significant differences between left and right hemisphere (observer 1 (p = 0.390), observer 2 (p = 0.722)). SI ratio DCN-to-pons at the right hemisphere was measured in median with 0.997 (0.860--1.072) for observer 1 and 0.991 (0.887--1.071) for observer 2, and at the left hemisphere with 0.999 (0.906--1.111)) for observer 1 and 0.989 (0.884--1.089) for observer 2. ([Table 4](#pone.0227649.t004){ref-type="table"})

10.1371/journal.pone.0227649.t004

###### Intraclass-correlation coefficient (ICC).
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                                ICC     confidence interval   
  --------------------- ------- ------- --------------------- -------
  SI DCN                left    0.999   0.998                 0.999
  SI Pons               0.999   0.998   1.000                 
  SI ratio              0.994   0.989   0.999                 
  SI ratio difference   0.949   0.847   0.983                 
  SI DCN                right   0.999   0.998                 1.000
  SI Pons               0.999   0.998   0.999                 
  SI ratio              0.910   0.811   0.957                 
  SI ratio difference   0.863   0.592   0.954                 

Intraclass-correlation coefficient (ICC) between observer 1 and 2. Displayed as mean and confidence interval for SI measurements at the DCN and Pons, for SI ratios and SI ratio differences in the left and right hemisphere

SI ratio differences between the first and the last MRI examination of the patients showed no significant differences, whether at the left nor at the right hemisphere (observer 1 (p = 0.831), observer 2 (p = 0.163)). SI ratio differences between the first and the last MRI examination of the patients was measured at the right hemisphere in median with -0.011 (-0.125--0.069) for observer 1 and -0.021 (-0.100--0.043) for observer 2, and at the left hemisphere with -0.002 (-0.079--0.138) for observer 1 and -0.010 (-0.096--0.082) for observer 2. ([Table 1](#pone.0227649.t001){ref-type="table"}) Based on a one-sample t-test, the first and the last MRI examination was tested to be significant different from 0. For both observers, no significant difference from 0 was found (observer 1: p = 0.896/0.402; observer 2: p = 0.451/0.098 \[left/right\]).

LA-ICP-MS data {#sec018}
--------------

Visual assessment of LA-ICP-MS analysis as well as a quantitative analysis was performed with a limit of quantification (LOQ) of 220 ng gadolinium/g tissue and a limit of detection (LOD) of 67 ng/g. Gadolinium concentrations in the DCN of the research beagle dog could be determined between 1.5 to 2.5 μg gadolinium/g tissue, 35 months after last gadodiamide injection. In agreement with the visual assessment of the DCN, gadolinium levels were higher in the DCN than in the surrounding area of the DCN. A co-localisation of Gd and zinc (Zn) was detectable, both increasingly detectable in vessels, especially at the DCN. Furthermore, an anti-correlation with phosphorus (P) was detectable, which is visible in μXRF and LA-ICP-MS. The results are summarized in [Fig 2](#pone.0227649.g002){ref-type="fig"}.

![Representative results for the LA-ICP-MS analyses of two cryo cerebellum samples of one dog treated with gadodiamide 35 months before euthanasia.\
Anatomy is shown on histological and μXRF images. LA-ICP-MS results are displayed as quantitative distribution map of gadolinium (^158^Gd) and as qualitative distribution maps of phosphorus (^31^P), iron (^57^Fe) and zinc (^66^Zn). LA-ICP-MS analyses were performed with a laser spot size of 10 μm and a limit of detection at 67 ng/g (LOD). A clear colocalization of gadolinium and zinc displays in both samples.](pone.0227649.g002){#pone.0227649.g002}

Discussion {#sec019}
==========

The current restrospective clinical study is the first study observing multiple gadodiamide applications in veterinary patients in a clinical set-up. The background of this study was the ongoing debate about the clinical relevance of hyperintensities of the DCN after multiple GBCA applications in humans. The hypothesis of this study was that there is a detectable increased hyperintensity on non-enhanced T1 weighted sequences in the DCN of dogs after multiple gadodiamide administrations and a measurable gadolinium retention in the cerebellum of dogs after chemical analysis based on LA-ICP-MS. The hypothesis has to be partially rejected.

This study showed 1) no hyperintensities on non-enhanced T1 weighted sequences in the clinical dog patients and 2) a Gd concentration of 1.5 to 2.5 μg gadolinium/g tissue in the brain of a research beagle dog 35 months after last gadodiamide injection.

With these findings, our study supports the hypothesis that a specific threshold is needed to identify hyperintensities on unenhanced T1-weighted images. It seems likely that the data of this dog patient population was not exposed to gadodiamide in an amount to exceed this threshold. With a median cumulative dose of 6.83 mmol/animal (range 0.54 to 16.65mmol/animal) the clinical dataset shows much less cumulative GBCA dose as compared to published reports from human medicine \[[@pone.0227649.ref001]\] or animal experiments.\[[@pone.0227649.ref053]\] Even if a superior brain clearance of macrocyclic GBCAs over linear GBCAs is described\[[@pone.0227649.ref054], [@pone.0227649.ref055]\] and all dogs of this study got a linear GBCA administration, the cumulative dose did not reach a visible level of hyperintensities after 2--3 administrations. We determined mean SI ratio differences between first and last MRI examination between 0.2% and 6.9% (range -12.5% to 13.8%), which was not significantly different from 0. ([Table 1](#pone.0227649.t001){ref-type="table"}) This is much lower than in the study of Hu et al., were an SI increase between first and most recent MRI examination with an increase of 18.6% ± 12.7% (range 0.5% to 47.5%) for the DCN was reported.\[[@pone.0227649.ref014]\] In the study of Hu et al., human patients received a significant number of subsequent GBCA examinations, ranging between 5 and 37. Weberling et al. described a significant SI increase in the DCN after at least 5 consecutive GBCA injections of gadobenate dimeglumine.\[[@pone.0227649.ref013]\]

Although the retrospective MRI study did not indicate any visible effect of SI increase after multiple gadodiamide exposures, further studies based on LA-ICP-MS showed that the optical threshold was not reached for a potential visible effect. Most of the dog patients in this study had a history of neoplastic or neurological disease as reason for MRI examination ([Table 1](#pone.0227649.t001){ref-type="table"}). In the patient records of the dogs, no side effects were linked with the contrast media application. This result is of clinical relevance for all current and future patients in veterinary medicine, which have a history of diagnosed brain tumors (such as meningiomas gliomas, nerve sheeth tumors, pituitary adenomas) or meningoencephalitis. Recurrent MRI examination are of interest in veterinary medicine mainly in dog patients after radiation therapy for follow ups and/or recidive pathologies. Our dataset showed that mostly not more than two MRI examinations with GBCA are performed during clinical work-up in veterinary medicine. This is a clear difference in comparison with human medicine, were more than 35 linear GBCA administrations to a single patient are reported.\[[@pone.0227649.ref018]\]

Even if there is no clinically visible hyperintensity on unenhanced T1-weighted MR images, this does not mean there is no deposition of gadolinium through gadodiamide application after multiple contrast media administrations in dogs. From human medicine it is known that approximately 6 injections of linear GBCAs are needed, before hyperintensities in the DCN become detectable on MRI\[[@pone.0227649.ref007], [@pone.0227649.ref056]\] On the other hand, gadolinium deposition was detectable after a single injection of linear GBCAs based on LA-ICP-MS measurments in the brain of sheep.\[[@pone.0227649.ref025]\] This study confirms gadolinium detection in the brain of a research beagle dog based on the chemical analysis of the Gd content. After three examinations, two times with 1x0.1 mmol/kg and once with 3x0.05 mmol/kg gadodiamide, Gd was measurable 35 month after the last administration. Accordingly, it could be shown in this study that the described Gd deposition in the brain of different species similarly occurs in dogs. Therefore, our findings support the hypothesis of irreversible or long lasting Gd deposition at the DCN. The current explanation about the pathomechanism is based on de-chelation effects of linear GBCA and transmetalation in co-localization with other elements, such as Fe, Co, Cu, Zn.\[[@pone.0227649.ref025], [@pone.0227649.ref057]\] We could show similar effects in the research beagle dog, which supports the ongoing discussion. As dogs are a widely used species for translational medicine and model for lots of pre-clinical studies during the approval of new medical products for human medicine, the results of our study should be recognized for all translational studies in future.

Even if the pathomechanism is not clarified at the moment and there are ongoing studies about differences between linear and macrocyclic GBCAs, from a scientific and ethical point of view it is mandatory to reduce the GBCA administration to the essential number with diagnostic importance for the patients. At the same time it is important to maintain the benefit of GBCA as long as there are no valuable alternative contrast media available. This should be done with respect to the risk of Gd deposition and its accumulation during recurrent contrast agent administrations.

As one of the limitations of this study, we have to mention that the number of patients and the number of gadodiamide administrations was lower than in comparable restrospective human studies. The reason is that in veterinary medicine dogs, as the most used private owned species, will not be imaged more often in MRI. This can be explained by the costs (payed by the owner) and the shorter life-span of a dog in comparison to humans. As our data reflects the daily business in a large university hospital, this was the maximum available data, which provides a relevant veterinary insight into this topic. Unfortunately, we did not have an MRI of the research beagle dogs brain, who had multiple gadodiamide administrations before euthanasia. This was caused by the fact that the brain of the dog was used as an add-on to another unrelated study which focused on other regions than the animals brain during MRI examination. It is a beneficial circumstance to have the results of the chemical analysis from this dog, even if there is no associated MRI of the brain. Based on the gained knowledge that an increased signal intensity of the brain might only be visible when the number of GBCA injections surpasses a certain threshold\[[@pone.0227649.ref034]\], it may have been questionable if this threshold would have been exceeded or not. According to the current knowledge, gadolinium first becomes visible in MRI if a threshold of approximately 1 μg gadolinium/g tissue is exceeded.\[[@pone.0227649.ref025]\] We assessed between 1.5 to 2.5 μg gadolinium/g tissue in the DCN of the research beagle dog, which would have caused a signal intensity change in MRI. Currently published case reports and research studies describe LA-ICP-MS as a useful tool to measure the quantities of retained gadolinium in human\[[@pone.0227649.ref019], [@pone.0227649.ref058], [@pone.0227649.ref059]\] and rodent tissues\[[@pone.0227649.ref047], [@pone.0227649.ref060]\]. Potential risk factors with effect on Gd retention described are ongoing neuroinflammation\[[@pone.0227649.ref060]\] or primary gliomas\[[@pone.0227649.ref059]\]. Additionally, any type of inflammation can negatively influence the blood brain barrier permeability\[[@pone.0227649.ref061]\] and therefore could be potential risk factor for gadolinium retention. In this study LA-ICP-MS was performed in the brain of a healthy research beagle dog, which was considered to be not influenced by clinical factors. On the other side the dataset of this study includes patients showing exactly such types of diseases with potential effect on gadolinium retention. The question how and in which quantity the underlying diseases or a reduced blood-brain-barrier influenced the gadolinium retention in the brain can not be estimated and has to be evaluated in further studies.

Another potential confounding factor for all clinical studies is the time between last GBCA administration and the MRI examination to detect hyperintensities in the DCN or until LA-ICP-MS measurement of gadolinium, as this time is crucial to differentiate between the soluble and insoluble form of gadolinium. In this study the median number of days between last GBCA application and MRI examination was 136 (range 24 to 582days). Accordingly there was enough gadolinium-free-time to detect insoluble gadolinium deposits only.

In conclusion, we could show that no hyperintensities on non-enhanced T1 weighted sequences in the clinical dog patients after 2--3 gadodiamide administrations of 0.1 mmol/kg were detactable and that between 1.5 to 2.5 μg gadolinium/g tissue could be determined in the brain of a research beagle dog 35 months after his last gadodiamide injection. The importance and clinical relevance of gadolinium retention of subvisible contents, the pathomechanism and the potential side effects based on Gd deposition still requires further investigation.
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